NCT01065727

Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis

Study Impact, on Clinical Outcomes, Quality of Life and Costs of 2 Therapeutic Strategy (Monthly Natalizumab Versus Mitoxantrone Then Immunomodulator) at 3 Years of Follow-up for Aggressive Remitting Multiple Sclerosis

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 250 (estimated)
• Sponsor: Rennes University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Cost-effectiveness study of 2 disease-modifying therapies (natalizumab versus mitoxantrone followed by immunomodulator) in the management of aggressive remitting multiple sclerosis

Conditions

• Multiple Sclerosis

Interventions

Type	Name	Description
OTHER	mitoxantrone - immunomodulator	mitoxantrone during 6 months and followed by immunomodulator during 2 years and half
OTHER	natalizumab	monthly natalizumab during 3 years

Timeline

• Start date: 2010-02-01
• Primary completion: 2016-02-01
• Completion: 2019-02-01
• First posted: 2010-02-09
• Last updated: 2012-12-03

Locations

2 sites across 1 country: France